Summarized by Masters of Longevity from PR Newswire.
Reports clinical results showing a transformer Base Editor (tBE) autologous HSPC therapy induced durable remission across diverse β-hemoglobinopathy genotypes, including sickle cell disease and transfusion-dependent β-thalassemia.
Key Takeaways
- All four non-Chinese patients treated with CS-101/CS-206 achieved durable clinical remission without transfusions or vaso-occlusive crises.
- TBE produced rapid hematopoietic engraftment with neutrophil recovery at day 13 and platelet recovery at day 21 in the SCD patient.
- No off-target edits or product-related adverse events were detected across treated patients during median follow-up of ~16–18 months.
